At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
linsitinib +1 moredrug
Likely dose
linsitinib 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of OSI-906 in Patients With Asymptomatic or Mildly Symptomatic (Non-Opioid Requiring) Metastatic Castrate Resistant Prostate Cancer (CRPC)
In Brief
A Phase 2 clinical trial evaluating linsitinib and laboratory biomarker analysis for Adenocarcinoma of the Prostate and 3 related conditions. Completed, enrolled 17 participants across 2 sites.
Detailed Summary
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2012
First PostedFeb 2012
Primary CompletionNov 2012
TodayJul 2026
First PostedFeb 15, 2012
Enrollment StartFeb 1, 2012
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.4 years ago
Interventions
linsitinibdrug
Oral Linsitinib 150mg, twice a day, days 1- 28
laboratory biomarker analysisother
Correlative studies